139 related articles for article (PubMed ID: 23822603)
21. Augmentation therapy in alpha-1 antitrypsin deficiency.
Heresi GA; Stoller JK
Expert Opin Biol Ther; 2008 Apr; 8(4):515-26. PubMed ID: 18352854
[TBL] [Abstract][Full Text] [Related]
22. Functional and antigenic concentrations of alpha-1-proteinase inhibitor after administration for the prevention of chronic lung disease of prematurity.
Stiskal JA; Ito S; Cox DW; Shennan AT; O'Brien KK; Kelly EN; Longley TB; Rabinovitch M; Dunn MS
Biol Neonate; 1999 Sep; 76(3):134-43. PubMed ID: 10460951
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
Balbi B; Ferrarotti I; Miravitlles M
Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
[No Abstract] [Full Text] [Related]
24. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
[TBL] [Abstract][Full Text] [Related]
25. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.
Dirksen A; Piitulainen E; Parr DG; Deng C; Wencker M; Shaker SB; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1345-53. PubMed ID: 19196813
[TBL] [Abstract][Full Text] [Related]
26. [Prolastin in the treatment of mild emphysema in patients with alpha 1-protease inhibitor deficiency].
Ulrik CS; Dirksen A; Kok-Jensen A
Ugeskr Laeger; 1992 Mar; 154(12):811-2. PubMed ID: 1553776
[No Abstract] [Full Text] [Related]
27. Alpha-1-antitrypsin replacement therapy: current status.
Abusriwil H; Stockley RA
Curr Opin Pulm Med; 2006 Mar; 12(2):125-31. PubMed ID: 16456382
[TBL] [Abstract][Full Text] [Related]
28. Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component.
Lomas DA; Elliott PR; Carrell RW
Eur Respir J; 1997 Mar; 10(3):672-5. PubMed ID: 9073003
[TBL] [Abstract][Full Text] [Related]
29. Safety of biweekly α
Greulich T; Chlumsky J; Wencker M; Vit O; Fries M; Chung T; Shebl A; Vogelmeier C; Chapman KR; McElvaney NG;
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30237305
[TBL] [Abstract][Full Text] [Related]
30. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
31. Successful α1-antitrypsin replacement therapy in a patient with α1-antitrypsin deficiency and granulomatosis with polyangiitis.
Hernández Pérez JM; Fumero García S; Alvarez Pío A
Rheumatology (Oxford); 2013 Apr; 52(4):755-7. PubMed ID: 22923761
[No Abstract] [Full Text] [Related]
32. Alpha-1-antitrypsin and other proteinase inhibitors.
Miravitlles M
Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
[TBL] [Abstract][Full Text] [Related]
33. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency.
Tirado-Conde G; Lara B; Miravitlles M
Ther Adv Respir Dis; 2008 Feb; 2(1):13-21. PubMed ID: 19124355
[TBL] [Abstract][Full Text] [Related]
34. alpha1-Antitrypsin deficiency: best clinical practice.
Kalsheker NA
J Clin Pathol; 2009 Oct; 62(10):865-9. PubMed ID: 19783716
[TBL] [Abstract][Full Text] [Related]
35. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products.
Cowden DI; Fisher GE; Weeks RL
Curr Med Res Opin; 2005 Jun; 21(6):877-83. PubMed ID: 15969888
[TBL] [Abstract][Full Text] [Related]
36. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema.
Wewers MD; Casolaro MA; Sellers SE; Swayze SC; McPhaul KM; Wittes JT; Crystal RG
N Engl J Med; 1987 Apr; 316(17):1055-62. PubMed ID: 3494198
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use.
Karnaukhova E; Ophir Y; Golding B
Amino Acids; 2006 Jun; 30(4):317-32. PubMed ID: 16773239
[TBL] [Abstract][Full Text] [Related]
38. Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.
Koepke J; Dresel M; Schmid S; Greulich T; Beutel B; Schmeck B; Vogelmeier CF; Janciauskiene S; Koczulla AR
PLoS One; 2015; 10(1):e0117497. PubMed ID: 25635861
[TBL] [Abstract][Full Text] [Related]
39. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
40. Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus.
Rachmiel M; Strauss P; Dror N; Benzaquen H; Horesh O; Tov N; Weintrob N; Landau Z; Ben-Ami M; Haim A; Phillip M; Bistritzer T; Lewis EC; Lebenthal Y
Pediatr Diabetes; 2016 Aug; 17(5):351-9. PubMed ID: 26073583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
